A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

Trial Profile

A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

Suspended
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Niraparib (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms GALAHAD
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 07 Nov 2017 According to a TESARO Inc. media release, data from this trial will support a planned regulatory submission in 2019.
    • 27 Sep 2017 Planned End Date changed from 10 Oct 2019 to 31 Dec 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top